| 1 |
quality-adjusted life-year
(3908 times)
|
Medicine
(425 times)
|
ICER (842 times)
ICERs (245 times)
WTP (137 times)
|
1985 Parameter estimates for a QALY utility model.
|
| 2 |
quality-adjusted life expectancy
(11 times)
|
Health Services
(3 times)
|
ICER (3 times)
3D-CRT (1 time)
BMI (1 time)
|
1994 Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis.
|
| 3 |
cost-per-quality-adjusted life year
(9 times)
|
Health Services
(2 times)
|
DALY (2 times)
ICERs (2 times)
NICE (2 times)
|
2008 The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
|
| 4 |
quality of life year
(8 times)
|
Gastroenterology
(2 times)
|
ICER (3 times)
ACS (1 time)
CT (1 time)
|
2004 Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
|
| 5 |
quality-adjusted LY
(8 times)
|
Health Services
(2 times)
|
LY (6 times)
ICERs (2 times)
mCRC (2 times)
|
2005 Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain.
|
| 6 |
Quality of Life Adjusted Years
(6 times)
|
Neurology
(1 time)
|
ACCI (1 time)
AF (1 time)
BBF (1 time)
|
2000 The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis.
|
| 7 |
quality-adjusted year of life
(5 times)
|
Vascular Diseases
(1 time)
|
AMI (1 time)
CI (1 time)
HPV (1 time)
|
2001 Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
|
| 8 |
quality of life
(4 times)
|
Acquired Immunodeficiency Syndrome
(1 time)
|
BMT (1 time)
BS (1 time)
CT (1 time)
|
2007 Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
|
| 9 |
quality
(3 times)
|
Medicine
(2 times)
|
ETV (1 time)
GDP (1 time)
HBV (1 time)
|
2015 [Clinical and economic benefits of the new antidiabetic drugs in the Czech Republic].
|
| 10 |
quality life year
(3 times)
|
Hospitals
(1 time)
|
COVID-19 (1 time)
ETV (1 time)
LVD (1 time)
|
2009 Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil.
|
| 11 |
Quality Ajusted Life Year
(2 times)
|
Medicine
(1 time)
|
ICER (2 times)
LQT (1 time)
PICANT (1 time)
|
2015 Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis.
|
| 12 |
quality of life impact
(2 times)
|
Communicable Diseases
(1 time)
|
CER (1 time)
LVAD (1 time)
|
1999 [Epidemiology and cost-effectiveness analysis of hepatitis A vaccination in Liuzhou City].
|
| 13 |
quality-adjusted survival
(2 times)
|
Neoplasms
(1 time)
|
BCBM (1 time)
CI (1 time)
NHS (1 time)
|
2006 Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases.
|
| 14 |
quality-associated life year
(2 times)
|
Female Urogenital Diseases
(1 time)
|
ASC (1 time)
DS (1 time)
ICER (1 time)
|
2013 The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
|
| 15 |
QoL-adjusted life year
(1 time)
|
Vascular Diseases
(1 time)
|
QOL (1 time)
|
2011 Cost and cost-effectiveness of cardiac surgery in elderly patients.
|
| 16 |
Quality Adjusted Life Year calculations
(1 time)
|
Medicine
(1 time)
|
TTO (1 time)
|
2012 Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.
|
A Search Service for Abbreviation / Long Form